MBRX — Moleculin Biotech Inc
NASDAQ · Healthcare · Biotechnology
$0.68
+$0.03 (+4.62%)
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on NASDAQ. It is led by Walter V. Klemp, based in 5300 Memorial Drive, Houston, TX, United States, 77007, with about 17 employees. Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Latest reported MBRX revenue for 2025-09-30 was $0. Net income was -$25.4M. MBRX currently screens at market cap $8.2M.
Use this MBRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MBRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MBRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Moleculin Biotech Inc even when a live quote feed is slow.
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX Key Statistics
Market Cap
$8.19M
Volume
453,808
Previous Close
$0.61
Day Range
$0.59 – $0.66
EPS
$0.00
Revenue
$0.00
Net Income
-$21.76M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
17
MBRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$21.76M | -$29.77M | -$29.02M | -$15.89M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$16.93M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.30M
Operating Cash Flow
-$23.86M
Free Cash Flow
$0.00
Moleculin Biotech Inc Company Information
- Co-Founder, Chairman, President & CEO
- Walter V. Klemp
- Headquarters
- 5300 Memorial Drive, Houston, TX, United States, 77007
- Website
- moleculin.com
- Phone
- (713) 300-5160
- IPO / Founded
- 2016-06-02
- Sector
- Healthcare
- Industry
- Biotechnology